Finerenone Slows Kidney Decline in CKD Patients Without Diabetes

Chronic kidney disease affects hundreds of millions worldwide, and most cases occur in people without diabetes — a population that has had limited targeted treatment options. The FIND-CKD trial, published in the New England Journal of Medicine and presented at the European Renal Association congress, now changes that picture by demonstrating that finerenone meaningfully slows kidney function decline in non-diabetic CKD patients.

The trial randomized 1,584 adults with CKD, albuminuria, and no diabetes. All were already on RAS inhibitor therapy. Half received finerenone (10 or 20 mg daily) and half received placebo. Over 32 months, those on finerenone lost kidney filtration capacity at a rate of -3.3 mL/min/1.73 m² per year, compared to -4.0 in the placebo group — a statistically significant difference matching what has been seen with SGLT2 inhibitors and RAS inhibitors in prior studies.

Beyond kidney filtration rates, finerenone cut the composite risk of major kidney or cardiovascular events by 23%, a clinically important finding given that CKD patients face elevated heart disease risk. The cardiovascular benefit alone trended favorably, though it did not reach statistical significance in this trial.

Notably, about 17% of participants were already using SGLT2 inhibitors, and finerenone's benefits held up equally in that subgroup. This suggests potential for stacking these therapies, though a direct combination trial has not yet been conducted. Benefits were also consistent across different glomerular disease subtypes.

The primary safety concern was hyperkalemia (elevated potassium), occurring in 17% of finerenone users versus 13% on placebo — a known class effect requiring monitoring. For health-conscious individuals with early CKD or kidney biomarker concerns, this trial signals that finerenone may soon become standard of care across a much broader patient population.